Clover Biopharmaceuticals Appoints Nicholas Jackson as President of Global R&D to Advance RSV Combination Vaccine Development
核心洞察
Clover Biopharmaceuticals (搜索) has appointed Nicholas Jackson, Ph.D., as President of Global R&D and Alliances to accelerate development of its RSV+hMPV±PIV3 combination vaccine (搜索) candidates.
Dr. Jackson brings over 27 years of vaccine development experience from leadership roles at GSK, Pfizer, and Sanofi Pasteur to advance Clover's respiratory vaccine portfolio.
The company's Trimer-Tag platform (搜索) technology has demonstrated safety across 40,000+ doses and recently reported positive Phase I clinical data in older adults.
Clover Biopharmaceuticals (搜索) announced the appointment of Nicholas Jackson, Ph.D., as President of Global R&D and Alliances, marking a strategic leadership addition as the company advances its respiratory syncytial virus (RSV (搜索)) combination vaccine candidates. Dr. Jackson will collaborate closely with CEO Joshua Liang to accelerate development of Clover's RSV+hMPV (搜索)±PIV3 (搜索) combination vaccines and establish global partnerships.
Veteran Vaccine Developer Returns to Clover
Dr. Jackson brings extensive experience from over 27 years in vaccine and infectious disease research and development, having led multiple successful global programs targeting viral and bacterial infectious diseases. His previous leadership positions include roles at GSK, Pfizer, and Sanofi, where he served as Head of Global Research for Sanofi Pasteur, overseeing vaccine research and early development activities worldwide. Most recently, he served as Executive Director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and Immunity (搜索) (NIVI).
"We are excited to welcome Nick back to Clover's leadership team. His extensive experience in leading global cross-border vaccine development and partnerships will be invaluable as we continue to advance our potential best-in-class and first-in-class RSV+hMPV±PIV3 combination vaccine (搜索) candidates leveraging our validated Trimer-Tag platform (搜索)," said Joshua Liang, Chief Executive Officer & Board Director of Clover.
Platform Technology Shows Clinical Promise
Clover's Trimer-Tag platform (搜索) technology has established a clinical safety database spanning over 40,000 doses and demonstrated commercial chemistry, manufacturing, and controls (CMC) scalability. The company recently announced positive Phase I clinical data for its RSV+hMPV±PIV3 combination vaccine (搜索) candidates in older adults, representing a significant milestone in respiratory vaccine development.
"I am honored to re-join Clover and look forward to helping advance and maximize global opportunities for Clover's RSV+hMPV±PIV3 combination vaccine (搜索) candidates, which have recently announced positive Phase I clinical data in older adults," said Dr. Jackson. "Additionally, Clover's Trimer-Tag platform (搜索) technology for vaccine development has a clinical safety database of 40,000+ doses and demonstrated commercial CMC scalability, which are critical for enabling late-stage development and globalization opportunities."
Strategic Focus on Global Partnerships
In his new role, Dr. Jackson will lead efforts to establish cross-border alliances aimed at maximizing the global impact of Clover's vaccine candidates and platform technology. The appointment reflects Clover's commitment to expanding its reach in addressing vaccine-preventable diseases through strategic partnerships.
"I look forward to leading potential cross-border alliances in our efforts to maximize the impact on public health for Clover's vaccine candidates and platform technology," Jackson stated.
Dr. Jackson holds a Bachelor of Science degree from Oxford Brookes University, a Master of Science from the London School of Hygiene & Tropical Medicine, and a doctorate from the University of Warwick in viral immunology. His academic background and industry experience position him to advance Clover's mission of developing innovative vaccines to address global health challenges.